PE20001546A1 - Epolitonas c-21 modificadas - Google Patents

Epolitonas c-21 modificadas

Info

Publication number
PE20001546A1
PE20001546A1 PE2000000140A PE0001402000A PE20001546A1 PE 20001546 A1 PE20001546 A1 PE 20001546A1 PE 2000000140 A PE2000000140 A PE 2000000140A PE 0001402000 A PE0001402000 A PE 0001402000A PE 20001546 A1 PE20001546 A1 PE 20001546A1
Authority
PE
Peru
Prior art keywords
alkyl
aryl
halogen
acil
heterocycle
Prior art date
Application number
PE2000000140A
Other languages
English (en)
Inventor
Soong-Hoon Kim
Nicole Glaser
Gregory D Vite
Thomas Leibold
Gerhard Hofle
Original Assignee
Biotechnolog Forschung Gmbh
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999107588 external-priority patent/DE19907588A1/de
Priority claimed from DE1999130111 external-priority patent/DE19930111A1/de
Application filed by Biotechnolog Forschung Gmbh, Bristol Myers Squibb Co filed Critical Biotechnolog Forschung Gmbh
Publication of PE20001546A1 publication Critical patent/PE20001546A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE REFIERE A LACTONAS MACROCICLICAS DE FORMULA I, DONDE P-Q ES UN ENLACE, EPOXIDO; G ES UN GRUPO TIAZOLIDINA SUSTITUIDO POR R1; GRUPO a; R ES H, ALQUILO; R1 ES (G4-G3)(G2)(G1)-C, (G1)(G2)(G5)-C, (G8-G7=)(G6)C, (G9=)(G6)C, (G10=C), ENTRE OTROS; R2 ES -O-N(+)-CO-G11, G1 ES H, ALQUILO, HALOGENO: G2 ES H, ALQUILO; G3 ES O, S, NZ1; G4 ES H, ALQUILO, OZ2, NZ2Z3, Z2CO, Z4SO2, GLICOSILO; G5 ES HALOGENO, N3, NCS, SH, CN, N(Z1)3(+), HETEROCICLO; G6 ES H, ALQUILO, CF3, OZ5, SZ5, NZ5Z6; G7 ES CZ7, N; G8 ES H, HALOGENO, ALQUILO, OZ10, ENTRE OTROS; G9 ES O, S, NH-NH; N=N; G10 ES N, CZ12; G11 ES H2N, ALQUILO, ARILO, Z1, Z6, Z9 SON H, ALQUILO, ACILO; Z2 ES H, ALQUILO, ARILO, HETEROCICLO; Z3, Z5, Z8, Z10 SON H, ALQUILO, ACILO, ARILO; Z4 ES ALQUILO, ARILO, HETEROCICLO, Z7 ES H, HALOGENO, ALQUILO, ARILO; CUANDO R1 ES (G4-G3)(G2)(G1)C NO SON SIMULTANEAMENTE G1 Y G2 SON H, G3 ES O, G4 ES H, Z2C ES O, Z2 ES ALQUILO. UN COMPUESTO PREFERIDO ES [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(AZIDOMETIL)-4-TIAZOLIL]-1-METILENETENIL]-7,11-DIHIDROXI-8,8,10,12,16-PENTAMETIL-4,17-DIOXABICICLO[14.1.0]HEPTADECAN-5,9-DIONA, ENTRE OTROS. TAMBIEN SE REFIERE AUN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I TIENE PROPIEDADES FUNGICIDAS Y CITOTOXICAS POR LO QUE PUEDE SER UTIL APRA EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS, CANCER
PE2000000140A 1999-02-22 2000-02-22 Epolitonas c-21 modificadas PE20001546A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999107588 DE19907588A1 (de) 1999-02-22 1999-02-22 C-21 Modifizierte Epothilone
DE1999130111 DE19930111A1 (de) 1999-07-01 1999-07-01 C-21 Modifizierte Epothilone

Publications (1)

Publication Number Publication Date
PE20001546A1 true PE20001546A1 (es) 2001-03-18

Family

ID=26051995

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000140A PE20001546A1 (es) 1999-02-22 2000-02-22 Epolitonas c-21 modificadas

Country Status (37)

Country Link
US (1) US6262094B1 (es)
EP (1) EP1157023B1 (es)
JP (1) JP4598957B2 (es)
KR (1) KR100685336B1 (es)
CN (1) CN1205208C (es)
AR (1) AR028815A1 (es)
AT (1) ATE254615T1 (es)
AU (1) AU771089B2 (es)
BG (1) BG64987B1 (es)
BR (1) BR0008379A (es)
CA (1) CA2360452C (es)
CO (1) CO5140093A1 (es)
CZ (1) CZ301498B6 (es)
DE (1) DE60006649T2 (es)
DK (1) DK1157023T3 (es)
EE (1) EE04852B1 (es)
ES (1) ES2209831T3 (es)
GE (1) GEP20033067B (es)
HK (1) HK1038923B (es)
HU (1) HUP0200076A3 (es)
ID (1) ID29829A (es)
IL (1) IL144501A0 (es)
LT (1) LT4944B (es)
LV (1) LV12755B (es)
MX (1) MXPA01008374A (es)
MY (1) MY120601A (es)
NO (1) NO320806B1 (es)
NZ (1) NZ513629A (es)
PE (1) PE20001546A1 (es)
PL (1) PL212545B1 (es)
PT (1) PT1157023E (es)
RU (1) RU2253652C2 (es)
SK (1) SK287200B6 (es)
TR (1) TR200102401T2 (es)
TW (1) TWI270546B (es)
UY (1) UY26024A1 (es)
WO (1) WO2000050423A1 (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229833B1 (en) 1996-11-18 2014-09-29 Biotechnolog Forschung Gmbh Epothilone d production process, and its use as cytostatic as well as phytosanitary agents
DE69734362T2 (de) * 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
GB9810659D0 (en) * 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
IL154986A0 (en) * 2000-09-22 2003-10-31 Biotechnolog Forschung Gmbh Triazolo-epothilone derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
JP2005500974A (ja) * 2000-10-13 2005-01-13 ザ ユニバーシテイ オブ ミシシッピー エポシロン類及び関連類似体の合成
SK8552003A3 (en) * 2001-01-25 2004-06-08 Bristol Myers Squibb Co Parenteral formulation containing epothilone analogs
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
HUP0400041A2 (hu) * 2001-02-20 2004-04-28 Bristol-Myers Squibb Co. Epotilonszármazékok alkalmazása makacs tumorok kezelésére szolgáló gyógyszerkészítmények előállítására
HUP0303175A2 (hu) 2001-02-20 2003-12-29 Bristol-Myers Squibb Co. Epotilonszármazékok alkalmazása makacs tumorok kezelésére alkalmas gyógyszerkészítmény előállítására
CA2440555A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
KR20040078123A (ko) * 2002-01-14 2004-09-08 노파르티스 아게 에포틸론 및 대사길항물질을 포함하는 조합물
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
US6900331B2 (en) * 2002-03-01 2005-05-31 University Of Notre Dame Derivatives of epothilone B and D and synthesis thereof
SI1485090T1 (sl) * 2002-03-08 2008-06-30 Novartis Ag Kombinacija vključujoča derivat epotilona in imidazotetrazinon
MXPA04008707A (es) * 2002-03-08 2006-03-08 Novartis Ag Combinaciones que comprenden derivados de epotilona y agentes de alquilacion.
DK1483251T3 (da) 2002-03-12 2010-04-12 Bristol Myers Squibb Co C3-cyano-epothilon-derivater
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
NZ536178A (en) * 2002-05-01 2007-10-26 Novartis Ag Epothilone derivative for the treatment of hepatoma and other cancer diseases
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
ES2281692T3 (es) 2002-08-23 2007-10-01 Sloan-Kettering Institute For Cancer Research Sintesis de epotilones, sus intermediarios, sus analogos y sus usos.
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
TWI291464B (en) 2002-09-23 2007-12-21 Bristol Myers Squibb Co Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
CA2499682A1 (en) * 2002-10-09 2004-04-22 Kosan Biosciences, Inc. Epo d + 5-fu/gemcitabine
EP1594854B1 (en) 2003-02-06 2010-09-01 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
US20050171167A1 (en) 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
KR20070084325A (ko) * 2004-11-18 2007-08-24 브리스톨-마이어스 스큅 컴퍼니 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
JP2009516753A (ja) * 2005-11-22 2009-04-23 ザ スクリップス リサーチ インスティテュート 高度に効力を持つエポチロンの化学合成
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
WO2008109075A2 (en) * 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
JP2010528115A (ja) * 2007-05-25 2010-08-19 ブリストル−マイヤーズ スクイブ カンパニー エポチロン化合物およびアナログの製造方法
US8449886B2 (en) 2008-01-08 2013-05-28 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
CA2722371C (en) * 2008-04-24 2016-06-21 Bristol-Myers Squibb Company Use of epothelone d in treating tau-associated diseases including alzheimer's disease
US20090311187A1 (en) * 2008-05-29 2009-12-17 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the Co-stimulatory pathway
US8119129B2 (en) * 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
AU2009350151B2 (en) 2009-07-20 2015-07-16 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
PL2496567T3 (pl) 2009-11-05 2018-01-31 Rhizen Pharmaceuticals S A Nowe benzopiranowe modulatory kinazy
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
US20130064831A1 (en) 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2011145035A1 (en) 2010-05-17 2011-11-24 Indian Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
EP3566719A1 (en) 2010-05-18 2019-11-13 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
SG194718A1 (en) 2011-05-04 2013-12-30 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinases
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
CN107082779A (zh) 2012-03-30 2017-08-22 理森制药股份公司 作为c‑met 蛋白激酶调节剂的新化合物
CN104768962B (zh) 2012-11-17 2017-04-05 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
CA2969665A1 (en) 2014-12-04 2016-06-09 Bristol-Myers Squibb Company Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
EA035888B1 (ru) 2015-06-29 2020-08-27 Бристол-Майерс Сквибб Компани Режимы дозирования иммунотерапевтических средств и их комбинаций
CN105153177B (zh) * 2015-09-28 2017-08-08 湖南大学 呋喃并色满肟烯/炔丙基醚及其制备方法与应用
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE75883C (de) W. schulte in Siegen und F. A. SAPP in Hillnhütten, Kreis Siegen Ofen zur Erzeugung von Cyanammonium
DE301115C (es)
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
EP1440973A3 (de) 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, Herstellung und Mittel
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
HU229833B1 (en) * 1996-11-18 2014-09-29 Biotechnolog Forschung Gmbh Epothilone d production process, and its use as cytostatic as well as phytosanitary agents
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
DE69734362T2 (de) 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19707303B4 (de) 1997-02-11 2006-05-11 Mitteldeutsches Bitumenwerk Gmbh Verfahren zur Gewinnung von Mikrowachsen, Paraffinen und Ölen aus Altkunststoffen oder Altkunststoffgemischen
CA2281105A1 (en) 1997-02-25 1998-09-03 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilones with a modified side chain
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
US6348551B1 (en) 1997-04-18 2002-02-19 Studiengesellschaft Kohle Mbh Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
JP2001510189A (ja) 1997-07-16 2001-07-31 シエーリング アクチエンゲゼルシヤフト チアゾール誘導体、その製造法および使用
DE59814067D1 (de) 1997-08-09 2007-09-06 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
EP1140928A4 (en) * 1998-12-23 2002-10-02 Bristol Myers Squibb Co MICROBIAL CONVERSION METHOD FOR PRODUCING AN EPOTHILONE

Also Published As

Publication number Publication date
EE200100437A (et) 2002-12-16
MXPA01008374A (es) 2003-06-06
NO320806B1 (no) 2006-01-30
GEP20033067B (en) 2003-09-25
IL144501A0 (en) 2002-05-23
RU2253652C2 (ru) 2005-06-10
AR028815A1 (es) 2003-05-28
KR20010102199A (ko) 2001-11-15
PL350179A1 (en) 2002-11-18
NO20014017D0 (no) 2001-08-17
DK1157023T3 (da) 2004-03-29
CZ20012991A3 (cs) 2002-01-16
PL212545B1 (pl) 2012-10-31
JP2002537395A (ja) 2002-11-05
CO5140093A1 (es) 2002-03-22
ID29829A (id) 2001-10-11
HK1038923B (zh) 2004-03-19
HUP0200076A2 (hu) 2002-12-28
DE60006649D1 (de) 2003-12-24
AU3234800A (en) 2000-09-14
JP4598957B2 (ja) 2010-12-15
KR100685336B1 (ko) 2007-02-23
WO2000050423A1 (en) 2000-08-31
SK287200B6 (sk) 2010-03-08
NO20014017L (no) 2001-10-17
BG64987B1 (bg) 2006-11-30
TR200102401T2 (tr) 2001-12-21
CN1205208C (zh) 2005-06-08
CA2360452C (en) 2011-07-26
LT2001086A (en) 2002-04-25
UY26024A1 (es) 2000-09-29
CA2360452A1 (en) 2000-08-31
CZ301498B6 (cs) 2010-03-24
LV12755B (lv) 2002-04-20
AU771089B2 (en) 2004-03-11
TWI270546B (en) 2007-01-11
BR0008379A (pt) 2002-09-24
EE04852B1 (et) 2007-06-15
NZ513629A (en) 2004-01-30
HK1038923A1 (en) 2002-04-04
ES2209831T3 (es) 2004-07-01
LV12755A (en) 2001-11-20
LT4944B (lt) 2002-08-26
BG105830A (en) 2002-03-29
US6262094B1 (en) 2001-07-17
CN1341114A (zh) 2002-03-20
EP1157023A1 (en) 2001-11-28
SK10782001A3 (sk) 2002-03-05
DE60006649T2 (de) 2004-09-30
EP1157023B1 (en) 2003-11-19
MY120601A (en) 2005-11-30
PT1157023E (pt) 2004-03-31
HUP0200076A3 (en) 2003-01-28
ATE254615T1 (de) 2003-12-15

Similar Documents

Publication Publication Date Title
PE20001546A1 (es) Epolitonas c-21 modificadas
KR950702982A (ko) 치환된 티아졸리딘디온 유도체(Substituted Thiazolidinedione Derivatives)
RU2353616C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JP2006501181A5 (es)
PE20020506A1 (es) Derivados de pirazol fusionados como inhibidores de la proteina cinasa
JP2019146572A5 (es)
PE20081532A1 (es) Compuestos novedosos
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
MA27624A1 (fr) Procede pour realiser une preparation enrobee
ATE557030T1 (de) Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung
BR0014596A (pt) Derivado de pirimidina, uso do mesmo, composição farmacêutica, e, método de tratar doenças ou condições médicas mediadas por citocinas
JP2005527576A5 (es)
BRPI0411365A (pt) derivados de aminopiridina
BR0313234A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, composição farmacêutica, e, processo para a preparação de um composto
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
RU2001125435A (ru) С-21 модифицированные эпотилоны
MXPA04000532A (es) Derivados de 8-metoxi-(1,2,4)-triazolo(1,5-a)piridina y su uso como ligandos receptores de adenosina.
BR0212484A (pt) Composto, processo para a preparação e uso do mesmo, método de tratamento de distúrbios alimentares em um animal de sangue quente, e, composição farmacêutica
DE60026404D1 (de) Verfahren zur Herstellung von Benzothiophen-Derivaten
FI944823A0 (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
AU2002357191A1 (en) Derivatives of isoindigo, indigo and indirubin and use in treating cancer
AR040077A1 (es) Composiciones farmaceuticas y metodos de uso de derivados de epotilona modificados por c-21
PE20001022A1 (es) Compuestos de pirazina
KR880011154A (ko) 벤즈옥사진 유도체 및 이의 제조방법
JP2005513103A5 (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal